text,labels
Normal-weight subjects showed significant blood oxygen level-dependent responses in the ventromedial prefrontal cortex ( vmPFC ) to food aromas compared with responses induced by the odor of an inedible object .,3
Female : 35.6 % .,3
"PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA , suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use .",4
"The SSM 30 g may be an effective , noninvasive alternative to health care provider-administered intravenous , intramuscular , or oral opioids for the management of moderate-to-severe acute pain .",4
"Comparing the responses between the odor of an inedible object and food aromas, the ventromedial prefrontal cortex (vmPFC) in normal-weight subjects exhibited significant blood oxygen level-dependent reactions.",3
The blood oxygen level-dependent responses in the ventromedial prefrontal cortex (vmPFC) of normal-weight individuals were notably higher when exposed to food aromas compared to the scent of an inedible object.,3
"In terms of blood oxygen level-dependent reactions, normal-weight participants displayed significant responses in the ventromedial prefrontal cortex (vmPFC) upon exposure to food aromas, contrasting with the response evoked by the odor of an inedible object.",3
"Food aromas prompted substantial blood oxygen level-dependent responses in the ventromedial prefrontal cortex (vmPFC) of normal-weight subjects, unlike the reactions caused by the scent of an inedible object.",3
"The ventromedial prefrontal cortex (vmPFC) of normal-weight individuals exhibited significant blood oxygen level-dependent responses when exposed to food aromas, in comparison to the responses triggered by the odor of an inedible object.",3
"When comparing the reactions evoked by food aromas and the scent of an inedible object, normal-weight participants demonstrated significant blood oxygen level-dependent responses in the ventromedial prefrontal cortex (vmPFC).",3
The percentage of females is 35.6.,3
35.6% of the population is female.,3
Women make up 35.6% of the total.,3
The female population accounts for 35.6%.,3
"Out of the total, 35.6% are female.",3
Females constitute 35.6% of the whole.,3
"PrEP has shown effectiveness in preventing HIV-1 transmission for women who use DMPA and men whose partners use DMPA, thereby suggesting it may reduce the heightened risks associated with DMPA use in acquiring and transmitting HIV-1.",4
The efficacy of PrEP in preventing HIV-1 among women using DMPA and men whose partners use DMPA suggests that it could help counter the potential risks of HIV-1 acquisition and transmission linked with DMPA use.,4
"In the context of women using DMPA and men with partners using DMPA, PrEP exhibits efficacy in preventing HIV-1, offering the possibility of mitigating the elevated risks associated with DMPA use.",4
"By demonstrating efficacy in mitigating the risks of HIV-1 acquisition and transmission associated with DMPA use, PrEP proves to be an effective method for women using DMPA and men whose partners use DMPA.",4
"PrEP has been found to be effective in preventing HIV-1 among women using DMPA and men with partners using DMPA, thereby indicating its potential to alleviate the heightened risks of HIV-1 acquisition and transmission associated with DMPA use.",4
The effectiveness of PrEP in preventing HIV-1 among women using DMPA and men whose partners use DMPA implies it can help reduce the potential risks linked to DMPA use in acquiring and transmitting HIV-1.,4
"The SSM 30 g has the potential to be a successful substitute, without the need for a healthcare professional, for administering intravenous, intramuscular, or oral opioids to treat intense acute pain.",4
"In the context of managing intense acute pain, the SSM 30 g could be a viable and noninvasive option that users can rely on, avoiding the requirement for healthcare professionals to administer intravenous, intramuscular, or oral opioids.",4
"An effective and noninvasive alternative for treating severe acute pain could be the SSM 30 g, potentially mitigating the need for healthcare providers to administer opioids intravenously, intramuscularly, or orally.",4
"The SSM 30 g may be a viable solution for moderating intense acute pain as an alternative to healthcare providers administering opioids intravenously, intramuscularly, or orally.",4
"Offering a noninvasive solution, the SSM 30 g could serve as an efficient alternative to opioids administered intravenously, intramuscularly, or orally by healthcare providers in managing severe acute pain.",4
"The SSM 30 g potentially provides an effective and noninvasive approach to managing moderate-to-severe acute pain, potentially obviating the need for healthcare providers to administer intravenous, intramuscular, or oral opioids.",4
